BCL2 and acute myeloid leukemia: Selective dependence on OXPHOS, associated to low glycolytic capacity indicates BCL-2 inhibitors (VTX) plus AZA, the standard of care for patients with newly diagnosed AML unfitted for intensive chemotherapy [39], as a therapy for resistant and relapsed APL patients.